Premium
Scholar Rock Holdings Corporation (SRRK)
NASDAQ
Hot Features
Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-04-23 | Ms. Kristina M. BurowIndependent Director | 89,80k | 820,32k | Derivative Exercise and Retained Stock | 4,75 - 26,78 | 103,24k | 668,20% |
| 2026-04-16 | Mr. Robert Keith WoodsCOO | -10,22k | 506,65k | Vente | 49,57 | 48,03k | -17,54% |
| 2026-04-16 | Dr. Akshay Krishnadas VaishnawPresident of R&D, Member of Scientific Advisory Board and Director | -12,25k | 607,09k | Vente | 49,57 | 58,52k | -17,30% |
| 2026-04-16 | Mr. Vikas SinhaCFO & Treasurer | -10,41k | 516,07k | Vente | 49,57 | 47,84k | -17,87% |
| 2026-04-16 | Mr. David L. HallalCEO & Chairman of the Board | -30,62k | 1,52M | Vente | 49,57 | 403,53k | -7,05% |
| 2026-02-23 | Mr. Mo QatananiChief Scientific Officer | -8,48k | 399,35k | Automatic Disposition | 46,94 - 48,48 | 0,00 | -100,00% |
| 2026-02-17 | Mr. Mo QatananiChief Scientific Officer | -7,99k | 371,71k | Vente | 46,53 | 8,48k | -48,50% |
| 2026-02-17 | Ms. Caryn ParlavecchioChief HR Officer | -9,04k | 420,38k | Vente | 46,53 | 86,86k | -9,42% |
| 2026-02-17 | Ms. Junlin HoGeneral Counsel & Corporate Secretary | -9,58k | 445,74k | Vente | 46,53 | 131,65k | -6,78% |
| 2026-02-17 | Dr. Jing L. MarantzChief Medical Officer | -4,16k | 193,42k | Vente | 46,53 | 29,39k | -12,39% |
| 2025-12-11 | Artal Group S.A.Société | 1,58M | 11,58M | Derivative Exercise and Retained Stock | 7,35 | 10,83M | 17,03% |
| 2026-01-22 | Mr. Mo QatananiChief Scientific Officer | -14,90k | 695,94k | Automatic Disposition | 45,87 - 46,85 | 85,66k | -14,82% |
| 2026-01-16 | Mr. Mo QatananiChief Scientific Officer | -8,41k | 373,88k | Vente | 44,48 | 100,56k | -7,71% |
| 2026-01-16 | Dr. Jing L. MarantzChief Medical Officer | -5,80k | 257,88k | Vente | 44,48 | 24,97k | -18,84% |
| 2026-01-16 | Ms. Caryn ParlavecchioChief HR Officer | -6,60k | 293,55k | Vente | 44,48 | 78,28k | -7,78% |
| 2026-01-16 | Ms. Junlin HoGeneral Counsel & Corporate Secretary | -8,02k | 356,53k | Vente | 44,48 | 121,47k | -6,19% |
| 2026-01-14 | Mr. Mo QatananiChief Scientific Officer | -13,11k | 349,65k | Derivative Exercise and Sale | 7,62 - 45,20 | 108,96k | - |
| 2026-01-13 | Mr. Vikas SinhaCFO & Treasurer | -16,76k | 715,44k | Vente | 42,70 | 33,25k | -33,51% |
| 2026-01-13 | Mr. Robert Keith WoodsCOO | -16,75k | 715,05k | Vente | 42,70 | 33,25k | -33,49% |
| 2026-01-13 | Dr. Akshay Krishnadas VaishnawPresident of R&D, Member of Scientific Advisory Board and Director | -20,44k | 872,70k | Vente | 42,70 | 45,77k | -30,87% |
| 2026-01-13 | Mr. David L. HallalCEO & Chairman of the Board | -57,45k | 2,45M | Vente | 42,70 | 371,65k | -13,39% |
| 2025-12-16 | Ms. Katie PengIndependent Director | -1,01k | 44,35k | Automatic Disposition | 43,88 - 44,63 | 14,84k | -6,35% |
| 2025-10-07 | Samsara BioCapital LLCSociété | 4,40k | 180,39k | Achat | 40,97 | 6,37M | 0,07% |
| 2025-10-07 | Samsara BioCapital LLCSociété | 25,20k | 1,00M | Achat | 39,31 - 40,18 | 6,37M | 0,40% |
| 2025-12-12 | Samsara BioCapital LLCSociété | 1,06M | 7,83M | Derivative Exercise and Retained Stock | 7,35 | 6,37M | 20,08% |
| 2025-12-04 | Mr. Mo QatananiChief Scientific Officer | -136,46k | 3,28M | Derivative Exercise and Sale | 4,86 - 45,21 | 108,96k | - |
| 2025-10-08 | Mr. David L. HallalCEO & Chairman of the Board | -205,00k | 0,00 | Other Disposition | - | 304,10k | -40,27% |
| 2025-10-03 | Samsara BioCapital LLCSociété | 500,44k | 18,81M | Achat | 35,61 - 39,52 | 5,30M | 10,42% |
| 2025-09-22 | Mr. Mo QatananiChief Scientific Officer | -3,35k | 102,85k | Automatic Disposition | 30,67 | 108,96k | -2,99% |
| 2025-09-16 | Mr. Mo QatananiChief Scientific Officer | -3,18k | 106,53k | Vente | 33,52 | 112,32k | -2,75% |
| 2025-09-16 | Ms. Katie PengIndependent Director | -1,01k | 32,73k | Automatic Disposition | 32,48 - 33,20 | 13,69k | -6,85% |
| 2025-08-18 | Ms. Caryn ParlavecchioChief HR Officer | -2,18k | 67,88k | Vente | 31,17 | 66,22k | -3,18% |
| 2025-07-16 | Dr. Jeffrey S. FlierIndependent Director & Member of Scientific Advisory Board | -11,14k | 445,69k | Automatic Disposition | 40,02 | 16,44k | -40,39% |
| 2025-07-08 | Mr. Mo QatananiChief Scientific Officer | -24,07k | 828,90k | Automatic Disposition | 34,44 | 0,00 | -100,00% |
| 2025-06-23 | Dr. Jeffrey S. FlierIndependent Director & Member of Scientific Advisory Board | -20,32k | 215,67k | Derivative Exercise and Sale | 21,62 - 32,74 | 27,57k | - |
| 2025-06-23 | Dr. Jeffrey S. FlierIndependent Director & Member of Scientific Advisory Board | -11,14k | 369,82k | Automatic Disposition | 33,21 | 27,57k | -28,77% |
| 2025-06-16 | Ms. Junlin HoGeneral Counsel & Corporate Secretary | -7,44k | 238,15k | Vente | 32,00 | 105,65k | -6,58% |
| 2025-06-16 | Ms. Katie PengIndependent Director | -3,03k | 96,89k | Automatic Disposition | 31,96 - 32,53 | 12,39k | -19,66% |
| 2025-06-16 | Mr. Mo QatananiChief Scientific Officer | -3,67k | 117,38k | Vente | 32,00 | 24,07k | -13,23% |
| 2025-06-16 | Ms. Caryn ParlavecchioChief HR Officer | -6,19k | 197,96k | Vente | 32,00 | 64,20k | -8,79% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
